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A negative sentinel lymph node (SLN) biopsy spares many breast cancer patients the complications associated with lymph node
irradiation or additional surgery. However, patients at high risk for nodal involvement based on clinical characteristics may remain
atunacceptablyhighriskofaxillarydiseaseevenafteranegativeSLNbiopsyresult.ABayesiannomogramwasdesignedtocombine
the probability of axillary disease prior to nodal biopsy with customized test characteristics for an SLN biopsy and provides the
probability of axillary disease despite a negative SLN biopsy. Users may individualize the sensitivity of an SLN biopsy based on
factorsknowntomodifythesensitivityoftheprocedure.Thistoolmaybeusefulinidentifyingpatientswhoshouldhaveexpanded
upfront exploration of the axilla or comprehensive axillary irradiation.
1.Introduction
In breast cancer, metastases to the axilla are associated with
an increased risk of distant micrometastatic disease [1–3].
Sentinel lymph node (SLN) biopsy has become standard
practice for evaluating the axilla in patients without palpable
lymph nodes [4]. This procedure involves injection of a trac-
er, usually a radioactive colloid, alone or in combination
with dye, into the tissue surrounding a tumor. Lymph nodes
with evidence of uptake are surgically removed. The SLN
procedure typically yields 1–5 nodes for pathologic exami-
nation whereas full axillary lymph node dissection (ALND)
can yield greater than 20 nodes when taken to completion.
On the other hand, SLN biopsy is associated with less pain,
lower rates of postsurgical lymphedema, and better arm mo-
bility when compared to full ALND [4]. Many patients
with a positive SLN biopsy go on to have ALND for both
diagnosticandtherapeuticpurposes.However,thereisgrow-
ing evidence that axillary irradiation may be used instead
of ALND in select cases with excellent results [5]. Indeed a
recent randomized trial showed that ALND oﬀered no ben-
e ﬁ to v e rS N Lb i o p s yi nt e r m so fl o c a lc o n t r o lo rs u r v i v a lt o
women with early clinical stage breast cancer who also re-
ceived radiation therapy [6].
Like any diagnostic test, SLN biopsy can yield false-
negative results. Several factors can aﬀect the sensitivity of2 International Journal of Breast Cancer
Table 1: Factors inﬂuencing the sensitivity of SLN biopsy.
Factor Sensitivity Reference
T1 89.7–93.3% [4, 7, 8]
T2-T3 82.0–92.6% [7, 9]
Grade [10]
1 95.7%
3 90.4%
Skill of surgeon 72.4–100% [8]
Method [11]
Combined dye and isotope 86.3–96.0%
Dye 85.7–90.4%
Isotope 86.3–97.8%
Number of SLN removed [10, 12]
1 82.3–89.1%
3 93.1–98.9%
5 99%
Medial tumor Decreases [8]
Age > 50 Decreases [8]
Obesity Decreases [10, 13]
an axillary SLN biopsy (Table 1). Large tumors have been
associated with decreased sensitivity (equivalently, higher
false-negative rates), perhaps because they access a greater
number of local lymphatic pathways and therefore have the
potentialforspreadingtoalargerdistributionofnodes[7,9].
Age-related fatty changes in nodes may decrease the capacity
f o rd y eo ri s o t o p eu p t a k e[ 8]. Medially located tumors may
drain more frequently to internal mammary nodes than
tumors located centrally or in the lateral breast [8]. Finally,
two prospective studies suggest that the sensitivity of SLN
biopsy correlates with the number of nodes removed [10,
12]. It should be noted that as techniques and protocols
have improved, the sensitivity of SLN biopsy has generally
improved. Nevertheless, the procedure remains imperfect,
and most recent studies demonstrate false-negative rates in
the range of 5–10% for small tumors [10, 12].
Breast cancer risk calculators are being increasingly used
to guide adjuvant systemic and local treatment [14–17].
Using such a calculator, the probability of axillary nodal
involvementforagivenpatientcanbeestimatedpriortoSLN
biopsy based on a number of prognostic factors including
age, tumor size, and histopathological features of the breast
cancer. One example of such a risk calculator was developed
at Memorial Sloan Kettering (MSKCC) and is available for
use online. This calculator was originally intended to spare
low-risk patients an SLN biopsy when the probability of
nodal involvement is low [14]. However, this calculated
probability may also beneﬁt high-risk patients when used in
combination with estimates of the false-negative rate of SLN
biopsytocalculatetheriskofhavingresidualnodaldiseasein
thesettingofanegativeSLN.Wedevelopedanomogramthat
combinesthisprobabilityofaxillarydiseasewithestimatesof
the sensitivity of SLN biopsy, to calculate the risk of residual
axillary disease despite a negative SLN biopsy.
2. Methods
Bayes’ rule combines the pretest probability of a given di-
agnosis with results from a test with known sensitivity and
speciﬁcity to yield a posttest probability of having the di-
agnosis. In this analysis, the pretest probability is the prob-
ability of having axillary disease prior to any nodal evalu-
ation; the posttest probability is the probability of axillary
disease given a negative SLN biopsy; the false-negative rate
(1-sensitivity) of SLN biopsy can be estimated from Table 1.
The speciﬁcity of SLN biopsy is by deﬁnition equal to one
(equivalently,theprobability ofapositive SLNinthe absence
of lymph node involvement disease is zero).
In this setting, Bayes’ rule takes the following form:
Post = pre ∗
(1 −sens)
pre ∗ (1 − sens)+

1 −pre

spec
. (1)
With “post” and “pre” deﬁned as posttest and pretest prob-
abilities, respectively, “sens” deﬁned as the sensitivity of SLN
biopsy, and “spec” deﬁned as the speciﬁcity of the procedure,
which in our situation is 1.
Using this formula we can estimate the probability that
a breast cancer patient has residual axillary disease despite a
negative SLN biopsy. A Bayesian nomogram was constructed
in MATLAB (MathWorks, v7.8) using the mathematical re-
lationship above. We used a range of pretest probabilities
from 5 to 85% and a 4 estimates of sensitivity (80%, 85%,
90%, and 95%) for the SLN biopsy procedure.
3. Results
We created a Bayesian nomogram for the probability of ax-
illary nodal involvement despite a negative SLN biopsy
(Figure 1). The nomogram was designed to be ﬂexible in
order to accommodate a variety of clinical scenarios. A range
ofsensitivityvaluesaredisplayedalongthemiddleaxisasdis-
crete points; the appropriate value for a given patient can
be estimated using Table 1. A line drawn through a given
pretest probability and sensitivity point will intersect with
the appropriate posttest probability (probability of having
residualaxillarydiseasedespiteanegativeSLNbiopsy)onthe
right-hand axis.
For example, the nomogram can be used to calculate
the risk of residual nodal disease in a 62-year-old woman
who presents after a lumpectomy revealing a 1.5cm, grade 2
invasive ductal carcinoma, hormone receptor-negative, with
no lymphovascular invasion and an SLN biopsy yielding 3
negative nodes. According to the MSKCC model her risk
of axillary disease prior to SLN biopsy is 19%. Assuming
95% for the sensitivity of SLN biopsy in this situation, the
nomogram reveals that the probability of having residual
axillary disease is 1.2%. Even if the sensitivity of SLN biopsy
was assumed to be 85%, the posttest probability remains low
at 3.4%.
Likewise, the nomogram can be used to calculate the
probability of residual axillary disease despite a negative SLN
biopsy in a woman at higher risk of axillary involvement.
A 64-year-old patient with a 2cm, grade 3, hormone recep-
tor-positive, invasive ductal carcinoma with lymphovascularInternational Journal of Breast Cancer 3
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Figure 1: Bayesian nomogram for probability of metastatic disease
as a function of pretest probability and negative SLN biopsy. The
“pre” or pretest probability of axillary disease can be estimated
using a risk calculator such as the one described [14]. The “sens” or
sensitivity of SLN biopsy can be estimated using Table 1. Positions
for the central dots are calculated assuming a SLN biopsy sensitivity
of 80%, 85%, 90%, or 95%; speciﬁcity is assumed to be 100%. The
calculationfortheexamplepatientisshownbythedottedline:ifwe
assume sensitivity of 85% for SLN biopsy and a pretest probability
of 62%, the posttest probability for axillary disease is 20% for this
patient even in the presence of a negative SLN biopsy.
invasion has a 62% pretest probability of metastases to the
axilla based on her pathology. Using a sensitivity of 85% for
SLN biopsy, the nomogram reveals that the probability of
residual axillary nodal involvement is 20%. In other words,
despite a negative SLN biopsy, she still has a 20% probability
of ﬁnding metastatic disease with completion ALND. If the
SLN biopsy procedure has a 95% sensitivity the nomogram
reveals that the risk of additional axillary disease after a neg-
ative SLN biopsy decreases to 7.5%.
Table 2: Calculated posttest probability of residual axillary disease
despite negative SLN biopsy for a range of pretest probabilities for
axillary disease with varying sensitivities of SLN biopsy.
Posttest probability of axillary disease
Pretest Sens 0.85 Sens 0.90 Sens 0.95
0.05 0.008 0.005 0.003
0.1 0.016 0.011 0.006
0.2 0.036 0.024 0.012
0.3 0.060 0.041 0.021
0.4 0.091 0.063 0.032
0.5 0.130 0.091 0.048
0.6 0.184 0.130 0.070
0.7 0.259 0.189 0.104
0.8 0.375 0.286 0.167
0.9 0.574 0.474 0.310
Table 2 provides a summary of ﬁndings for the posttest
probability of residual axillary disease despite negative SLN
biopsy for a range of pretest probabilities of axillary disease
p r i o rt oS L Nb i o p s ya te a c ho f3d i ﬀerent sensitivities for the
SLN procedure.
4. Discussion
The presence of axillary disease is the most important prog-
nostic factor in breast cancer. Disease in the axilla can indi-
cate biological aggressiveness and extent of tumor involve-
ment, often suggesting systemic spread and the need for ad-
ditional therapy. In addition, the link between locoregional
disease control and overall survival in breast cancer has been
ﬁrmly established by meta-analyses of randomized data [18].
The potential importance of ALND in select patients is un-
derscoredbyarecentanalysiswhichsuggestedasurvivalben-
eﬁt for women with macroscopic nodal disease that received
ALND as compared to women with SLN biopsy alone [19].
Additionally the NCIC CTG MA.20 trial which randomized
patients with high-risk breast cancer to postoperative whole-
breast (WB) radiotherapy alone versus WB plus regional
nodal irradiation showed improved locoregional control and
an even greater improvement in distant disease control in
the arm with regional nodal irradiation [20]. Therefore, the
risks of more extensive axillary treatment versus the risks of
missing occult disease must be carefully considered.
Our nomogram is intended to be ﬂexible and enable in-
creased personalization of cancer care. Speciﬁcally, our anal-
ysis is most applicable to two clinical scenarios and argues
that
(1) for a patient who had a negative SLN biopsy, but
still has a high posttest probability of axillary disease,
comprehensive axillary radiation may be warranted;
(2) for a patient who has not yet undergone any axillary
surgery, who has a high pretest probability of positive
axillary nodes based on clinical features and who also
has clinical characteristics that might decrease the4 International Journal of Breast Cancer
sensitivity of SLN biopsy (as in Table 1), expanded
axillary assessment up front may be warranted.
These conclusions seek to limit overtreatment in the
form of multiple surgeries (SLN biopsy followed by ALND)
and undertreatment in the form of omission of axillary ra-
diation in breast patients with high-risk disease.
We created a nomogram to estimate the risk of residual
axillary disease despite a negative SLN biopsy as a function
of the sensitivity of the SLN biopsy procedure and the pretest
probability of axillary disease prior to axillary evaluation.
Our nomogram reveals that for patients with a high pretest
probability of axillary metastases and factors associated with
a lower SLN biopsy sensitivity, the posttest probability of
axillary disease often remains high despite a negative biopsy.
While SLN biopsy is the appropriate test for most breast
cancer patients, a preemptive expanded assessment of the
axilla may be a better choice for high-risk patients or in
cases where an SLN biopsy is predicted to be less sensitive
(Table 1).
In contrast to other probability calculators which esti-
mate the risk of nonsentinel axillary nodal disease in a wom-
an with breast cancer only after a positive SLN, our decision
tool estimates the probability of nonsentinel axillary nodal
diseasewithout priorpathologicassessmentoftheaxilla[15–
17, 21]. The posttest probability obtained from the nom-
ogram presented can then be assessed to be acceptable or
not based on the speciﬁc clinical scenario. For example, a
predicted posttest probability greater than 20–25% may war-
rant consideration of a more thorough axillary assessment
upfront. Similarly, in cases where a negative SLN biopsy has
already been obtained, a posttest probability of greater than
10% may suggest the need for the addition of axillary ra-
diation.
In patients identiﬁed by the nomogram to have an unac-
ceptablyhigh-riskofresidualaxillarydiseasedespitenegative
SLN biopsy, more aggressive preemptive exploration of the
axilla will necessarily mean a higher risk of lymphedema,
nerve injury and general surgical complications compared to
SLN biopsy; nevertheless, with modern ALND where only
levels I-II are removed, these risks are less than observed
historically[20].Anotheroptionmaybealessmorbidlymph
node sampling procedure as was reported in the UK, where
at least 4 palpable lymph nodes are obtained by dissection
starting at the axillary tail [22]. For patients where a neg-
ative SLN biopsy has already been obtained, but a high
posttest probability of axillary disease remains, the addition
of axillary radiation therapy could be considered in lieu of
completion axillary dissection.
Use of this nomogram after a breast biopsy is not ex-
pected to result in excessive axillary treatment because it is
likely to slightly underestimate rather than overestimate the
probability of residual nodal disease. This is because the
MSKCC risk calculator used above to obtain a pretest prob-
ability of having nodal disease was validated with informa-
tion from complete pathologic specimens whereas, in prac-
tice, physicians are likely to substitute incomplete biopsy
specimens such as ﬁndings from core needle biopsy, result-
ing in underdetection (due to undersampling) of certain
negative prognostic factors, such as lymphovascular inva-
sion, multifocality, and higher-grade tumor areas, which if
found, increase the probability of having nodal disease.
Therefore, use of only biopsy information would lead to
underestimation of the pretest probability of having axillary
involvement,whichinturnwouldleadtounderestimationof
the posttest probability when using the nomogram. Another
possiblesourceoferrorassociatedwiththeuseofincomplete
biopsy specimens is that tumor size estimate entered into the
MSKCC risk calculator must be estimated indirectly, based
on imaging. However, assessment of tumor size by MRI,
mammography and ultrasound does appear to correlate well
with size as determined by pathologic exam [23, 24].
Although the recently published ACOSOG Z0011 and
NSABP B-32 trials show similar rates of local control in both
their SLN alone and ALND arms, the patients included in
these trials were conservatively chosen and by deﬁnition had
al o w - r i s kp r o ﬁ l e[ 6, 25]. For the average patient in these
trials, the risk of additional nodal disease after a negative
SLN biopsy according to our nomogram would be under 6%
even when using a low value of 85% as the sensitivity for
SLN biopsy. Therefore our nomogram would not change the
management of the average patient on these trials.
For high-risk patients systemic therapy recommenda-
tions are also unlikely to change based on the output of this
nomogram, because many of the factors which prompt addi-
tion of adjuvant therapy are the same factors that increase
the pretest (and therefore also posttest) probability of having
axillary disease. However, with regard to local management
of the axilla, using this nomogram may change manage-
ment, especially in light of the NCIC CTG MA.20 trial
which included high-risk patients and suggests that residual
untreated nodal disease may aﬀect distant disease even in the
absence of a clinically evident nodal recurrence.
This nomogram is anticipated to apply to the small pro-
portion of breast cancer patients who present with clinically
high-risk disease. Randomized studies for this subset are dif-
ﬁcult to perform because most breast cancer patients present
with early-stage disease. Therefore, Bayesian estimation of
risk based on a mathematically sound extrapolation from
available data is especially useful in this clinical situation.
Our nomogram is a particularly important tool for this
group of high-risk patients because they may beneﬁt from
more extensive surgery or axillary radiation.
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